[{"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-001", "question": "A 42-year-old man with acromegaly undergoes transsphenoidal resection of a growth hormone-secreting pituitary adenoma. Postoperatively, he develops polyuria with urine output exceeding 10 L/day and serum sodium of 152 mEq/L. What is the most appropriate treatment?", "options": ["Desmopressin acetate", "Fluid restriction", "Hypertonic saline infusion", "Demeclocycline", "Vasopressin infusion"], "answer": "A", "answer_index": 0, "explanation": "Postoperative diabetes insipidus from pituitary surgery causes polyuria and hypernatremia, treated with desmopressin to replace deficient antidiuretic hormone. Fluid restriction is for SIADH, not DI. Hypertonic saline worsens hypernatremia.", "generator_model": "grok-4-0709", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "target_topic", "source_label_raw": "Endocrine", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed130", "source_question_id": "20251216T182308874Z_grok-4-0709_seed130-018", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed130.jsonl", "pred": "A", "model_outputs": "The patient presents with polyuria (urine output exceeding 10 L/day) and hypernatremia (serum sodium of 152 mEq/L) following transsphenoidal resection of a pituitary adenoma. These symptoms are classic signs of central diabetes insipidus (DI). Pituitary surgery can disrupt the production or release of antidiuretic hormone (ADH, also known as vasopressin) from the posterior pituitary. ADH is crucial for water reabsorption in the kidneys; its deficiency leads to the excretion of large volumes of dilute urine and consequently can cause dehydration and hypernatremia if free water intake does not match the massive water loss.\n\nWe need to choose the most appropriate treatment to address this condition.\n\nA.  Desmopressin acetate (DDAVP) is a synthetic analog of ADH. It is the standard and most appropriate pharmacologic treatment for central diabetes insipidus. It acts on the kidneys to increase water reabsorption, reducing urine output and helping to correct hypernatremia and dehydration.\n\nB.  Fluid restriction is generally not sufficient or appropriate as the primary treatment for significant central DI, especially when urine output is as high as 10 L/day. While fluid intake should be monitored and encouraged, restricting fluids could worsen dehydration and hypernatremia in a patient who cannot conserve water due to ADH deficiency. Fluid restriction is more relevant in managing SIADH.\n\nC.  Hypertonic saline infusion is used to treat severe, symptomatic hyponatremia (low serum sodium). Administering hypertonic saline would exacerbate the patient's existing hypernatremia, which is the opposite of the desired effect.\n\nD.  Demeclocycline is a tetracycline antibiotic that can induce nephrogenic diabetes insipidus by impairing the kidney's response to ADH. It is used in the treatment of SIADH, not central DI. Using it here would worsen the condition.\n\nE.  Vasopressin infusion is the natural form of ADH and would also treat central DI by restoring water reabsorption. However, desmopressin acetate (DDAVP) is generally preferred for the management of central DI due to its longer duration of action, greater receptor selectivity (V2 receptors, mediating water reabsorption), and availability in various formulations (oral, nasal, injectable), which can facilitate more stable and convenient management compared to continuous intravenous infusion of vasopressin. Therefore, DDAVP is typically considered the \"most appropriate\" choice in routine clinical practice and exam scenarios for central DI unless specific reasons dictate otherwise.\n\nGiven the options, desmopressin acetate is the most appropriate treatment for central diabetes insipidus.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-002", "question": "A 50-year-old man with cirrhosis presents with massive hematemesis. Endoscopy reveals isolated gastric varices without esophageal involvement. CT shows splenic vein thrombosis. What is the most appropriate definitive management?", "options": ["Endoscopic band ligation", "Transjugular intrahepatic portosystemic shunt", "Balloon-occluded retrograde transvenous obliteration", "Splenectomy", "Beta-blocker therapy"], "answer": "D", "answer_index": 3, "explanation": "Isolated gastric varices due to splenic vein thrombosis (sinistral portal hypertension) are best managed with splenectomy to eliminate the inflow and prevent rebleeding. TIPS is ineffective as it does not address the isolated splenic vein pathology. Band ligation is temporary and not definitive for this etiology.", "generator_model": "grok-4-0709", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed130", "source_question_id": "20251216T182308874Z_grok-4-0709_seed130-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed130.jsonl", "pred": "C", "model_outputs": "The patient presents with massive hematemesis due to isolated gastric varices in the context of cirrhosis and splenic vein thrombosis. This is a critical scenario. Let's analyze the options:\n\nA. Endoscopic band ligation: While banding is a standard treatment for esophageal varices, it is generally less effective and carries higher risks for isolated gastric varices. Endoscopic injection sclerotherapy with cyanoacrylate glue is the preferred endoscopic treatment for bleeding gastric varices. Therefore, band ligation is not the most appropriate definitive management.\n\nB. Transjugular intrahepatic portosystemic shunt (TIPS): TIPS reduces portal pressure by creating a shunt. However, in patients with isolated gastric varices, especially those due to splenic vein thrombosis, TIPS can be contraindicated or lead to worsening of the gastric varices by diverting blood flow preferentially into them. It is generally avoided as a first-line treatment for isolated gastric varices.\n\nC. Balloon-occluded retrograde transvenous obliteration (BOTO): This term refers to an endovascular procedure where varices are embolized. In the case of splenic vein thrombosis causing isolated gastric varices, the blood backs up from the portal system into the gastric veins. A retrograde transvenous obliteration procedure aims to access these varices (often via a percutaneous transhepatic or transjugular route) and inject sclerosants or coils to obliterate them. This directly treats the bleeding source and is a highly appropriate definitive management for gastric varices, especially when caused by sinistral portal hypertension (like splenic vein thrombosis).\n\nD. Splenectomy: Splenectomy removes the spleen, which is the source of increased pressure in the splenic vein thrombosis scenario. However, splenectomy is a major surgery with significant risks (like overwhelming post-splenectomy infections) and does not directly address the underlying portal hypertension or potential residual thrombosis in other vessels. It is typically reserved for cases with severe hypersplenism or when other treatments fail. It is not usually the first-line *definitive* management for bleeding varices.\n\nE. Beta-blocker therapy: Beta-blockers are used for primary and secondary prophylaxis of esophageal variceal bleeding by reducing portal pressure. However, they are generally much less effective for managing gastric varices, particularly isolated gastric varices, and are not considered definitive management for active bleeding.\n\nGiven the presence of splenic vein thrombosis leading to isolated gastric varices, an embolization procedure like Balloon-occluded retrograde transvenous obliteration is a superior definitive management option compared to the others. It directly targets and obliterates the varices responsible for the bleeding.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-003", "question": "A 55-year-old man with idiopathic pulmonary fibrosis presents with acute worsening dyspnea. High-resolution CT shows new ground-glass opacities superimposed on fibrosis. Bronchoalveolar lavage reveals neutrophilia without infection. What is the most appropriate therapeutic approach?", "options": ["High-dose systemic corticosteroids", "Azathioprine addition to regimen", "Pirfenidone dose escalation", "Nintedanib initiation", "Lung transplantation evaluation"], "answer": "A", "answer_index": 0, "explanation": "High-dose systemic corticosteroids are the most appropriate for acute exacerbation of idiopathic pulmonary fibrosis, aiming to suppress inflammation despite limited evidence. Azathioprine is contraindicated due to increased mortality risk. Pirfenidone and nintedanib are antifibrotics for stable disease, not acute flares, and transplantation is for end-stage but not immediate management.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "source_question_id": "20251201T041413890Z_grok-4-0709_seed123-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251201T041413890Z_grok-4-0709_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251201T041413890Z_grok-4-0709_seed123.jsonl", "pred": "A", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe patient presents with an acute worsening of symptoms (dyspnea), new findings on CT (ground-glass opacities superimposed on fibrosis), and laboratory evidence of inflammation (neutrophilia) without infection. This clinical picture strongly suggests an acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF).\n\nThe management of acute exacerbations of IPF is primarily focused on addressing the underlying inflammation.\n- A. High-dose systemic corticosteroids: This is the traditional and widely used empirical treatment for acute exacerbations of IPF, aimed at reducing inflammation.\n- B. Azathioprine addition to regimen: While some guidelines recommend adding azathioprine (or cyclophosphamide) to corticosteroids for managing IPF exacerbations, this recommendation is based on low-quality evidence, and azathioprine is not used as monotherapy. It is an adjunct to corticosteroids.\n- C. Pirfenidone dose escalation: Pirfenidone is an anti-fibrotic medication used for the chronic management of IPF to slow disease progression. It is not indicated for the acute treatment of exacerbations.\n- D. Nintedanib initiation: Nintedanib is another anti-fibrotic medication used for chronic management of IPF. It is not indicated for the acute treatment of exacerbations.\n- E. Lung transplantation evaluation: While important for eligible patients with advanced IPF, lung transplantation evaluation is not the immediate therapeutic approach for managing an acute exacerbation.\n\nGiven that the exacerbation involves acute inflammation, high-dose systemic corticosteroids are the most direct and appropriate initial therapeutic approach to target the inflammatory process. While combination therapy with azathioprine might be considered according to some guidelines, corticosteroids alone represent the cornerstone of empirical treatment for the acute inflammatory insult in IPF exacerbations when infection is ruled out.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-004", "question": "A 45-year-old man with autosomal dominant polycystic kidney disease presents with acute flank pain and hematuria. Imaging reveals a 6 cm cyst with internal septations and hemorrhage. Renal function is preserved, but he develops fever and leukocytosis. Blood cultures are negative, but cyst aspiration yields purulent fluid positive for Escherichia coli. Despite appropriate intravenous antibiotics, his symptoms persist. What is the most appropriate next step in management?", "options": ["Switch to a different antibiotic based on sensitivity testing", "Perform percutaneous cyst drainage and sclerotherapy", "Initiate long-term suppressive antibiotic therapy", "Surgical decortication of the infected cyst", "Administer intraparenchymal antibiotic infusion"], "answer": "D", "answer_index": 3, "explanation": "Surgical decortication is indicated for persistent cyst infection in polycystic kidney disease when antibiotics and drainage fail, as it allows complete removal of infected material. Percutaneous drainage often fails due to viscous cyst contents and multiloculation, while sclerotherapy is not appropriate for infected cysts. Long-term suppression or antibiotic switches do not address the source of ongoing infection.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with a complicated renal cyst infection in the setting of ADPKD. Key findings include flank pain, hematuria, fever, leukocytosis, a purulent aspirate positive for E. coli, and persistence of symptoms despite appropriate intravenous antibiotics. This clinical scenario indicates that systemic antibiotics alone are insufficient to resolve the infection, likely due to poor drug penetration into the purulent, walled-off cyst.\n\nLet's analyze the options:\nA. Switch to a different antibiotic based on sensitivity testing: While adjusting antibiotics based on sensitivity testing is important, the prompt states the initial antibiotics were \"appropriate.\" Even with appropriate antibiotics, failure to resolve symptoms in a purulent cyst suggests a need for intervention beyond medication. If the initial treatment was empiric and sensitivities are now available, this would be considered. However, persistence implies a mechanical issue or lack of penetration.\n\nB. Perform percutaneous cyst drainage and sclerotherapy: This is a less invasive approach to remove the infected fluid and purulent material from the cyst. After drainage, sclerotherapy can be used to prevent recurrence by obliterating the cyst cavity. Given the failure of systemic antibiotics, drainage is a highly effective next step for infected cysts, especially when they are symptomatic and purulent.\n\nC. Initiate long-term suppressive antibiotic therapy: Suppressive therapy is generally used for recurrent infections or prophylaxis, not for an acute, persistent infection that doesn't respond to initial treatment. It does not address the source of the infection.\n\nD. Surgical decortication of the infected cyst: Surgical intervention is an option for infected cysts that are very large, resistant to less invasive treatments, recurrent, or complicated by abscess or fistula. However, percutaneous drainage is typically attempted first due to its lower morbidity.\n\nE. Administer intraparenchymal antibiotic infusion: This is not a standard or recognized treatment for renal cyst infections.\n\nConsidering that the patient's symptoms persist despite appropriate IV antibiotics, the most appropriate next step is to address the infected collection directly. Percutaneous drainage is the standard of care for symptomatic, infected renal cysts that fail to improve with antibiotics, being less invasive than surgical decortication.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-005", "question": "A 62-year-old woman with chronic lymphocytic leukemia develops petechiae and easy bruising. Laboratory studies show hemoglobin 9.2 g/dL, platelets 12,000/μL, and white blood cells 45,000/μL with 80% lymphocytes. Bone marrow biopsy reveals 90% infiltration by small lymphocytes. She has no active infection or bleeding. What is the most likely mechanism underlying her thrombocytopenia?", "options": ["Autoimmune destruction mediated by anti-platelet antibodies", "Bone marrow suppression from leukemic infiltration", "Hypersplenism with platelet sequestration", "Drug-induced thrombocytopenia from prior chemotherapy", "Microangiopathic hemolytic anemia with consumptive thrombocytopenia"], "answer": "B", "answer_index": 1, "explanation": "In advanced chronic lymphocytic leukemia, thrombocytopenia is primarily due to bone marrow infiltration by leukemic cells, crowding out normal hematopoiesis. Autoimmune thrombocytopenia occurs in only 1-2% of cases and typically responds to steroids, while hypersplenism is less common without massive splenomegaly. Drug effects or microangiopathy are not supported by the clinical scenario.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "B", "model_outputs": "The patient presents with severe thrombocytopenia (platelets 12,000/μL) with petechiae and easy bruising, along with a diagnosis of chronic lymphocytic leukemia (CLL). The most striking laboratory finding is a bone marrow biopsy showing 90% infiltration by small lymphocytes, consistent with advanced CLL.\n\nLet's evaluate the options:\n\nA. Autoimmune destruction mediated by anti-platelet antibodies: Immune thrombocytopenic purpura (ITP) is a common autoimmune complication of CLL. Antibodies directed against platelets lead to their accelerated destruction. This is a valid possibility in a CLL patient with thrombocytopenia.\n\nB. Bone marrow suppression from leukemic infiltration: The bone marrow is the site of platelet production. With 90% infiltration by CLL cells, there is significantly reduced space for normal hematopoietic stem cells and megakaryocytes. This overcrowding directly impairs megakaryopoiesis, leading to decreased platelet production. This is a very strong contender given the high percentage of infiltration.\n\nC. Hypersplenism with platelet sequestration: Splenomegaly is common in CLL. If the spleen is enlarged and overactive (hypersplenism), it can trap and destroy a larger proportion of circulating platelets. This can contribute to thrombocytopenia, but is often a secondary phenomenon.\n\nD. Drug-induced thrombocytopenia from prior chemotherapy: The case does not mention any prior chemotherapy. Therefore, this is less likely unless specific historical information is missing.\n\nE. Microangiopathic hemolytic anemia with consumptive thrombocytopenia: Conditions like TTP or HUS involve platelet consumption due to microthrombi, often associated with microangiopathic hemolytic anemia. While CLL can be associated with these, there is no mention of hemolysis (e.g., schistocytes, elevated LDH, low haptoglobin) in the provided data.\n\nComparing options A and B: Both autoimmune destruction and impaired production due to marrow infiltration are common causes of thrombocytopenia in CLL. However, the reported 90% bone marrow infiltration is a direct and extremely significant finding that profoundly impacts the bone marrow's ability to produce platelets. This level of infiltration would almost certainly lead to substantial suppression of normal hematopoiesis, including megakaryopoiesis. While autoimmune destruction can also occur and exacerbate thrombocytopenia, the pervasive infiltration described in the bone marrow biopsy is the most direct and evident mechanism for decreased production of platelets in this specific patient's presentation.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-006", "question": "A 28-year-old man with common variable immunodeficiency presents with recurrent sinopulmonary infections. Immunoglobulin levels show IgG 150 mg/dL, IgA <5 mg/dL, and IgM 20 mg/dL. He has absent responses to protein and polysaccharide vaccines. Genetic testing reveals a heterozygous mutation in the TACI gene. What is the most appropriate long-term management strategy?", "options": ["Monthly intravenous immunoglobulin replacement", "Prophylactic antibiotics with trimethoprim-sulfamethoxazole", "Hematopoietic stem cell transplantation", "Rituximab therapy to deplete B cells", "Interleukin-2 supplementation"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin replacement is the cornerstone of therapy for common variable immunodeficiency to prevent infections by providing passive immunity. Prophylactic antibiotics are adjunctive but not sufficient alone, while transplantation is reserved for severe cases with cellular defects. Rituximab and IL-2 are not standard for this humoral immunodeficiency.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "A", "model_outputs": "The patient presents with characteristic features of Common Variable Immunodeficiency (CVID), including recurrent sinopulmonary infections, profoundly low immunoglobulin levels (IgG, IgA, IgM), and poor vaccine responses. The identification of a TACI gene mutation further supports a diagnosis within the spectrum of antibody deficiencies. TACI is involved in B cell maturation and immunoglobulin class switching; mutations in this gene are found in a significant proportion of CVID patients.\n\nThe primary goal in managing CVID is to prevent infections by supplementing the deficient antibodies.\n\nLet's analyze the options:\nA. Monthly intravenous immunoglobulin replacement (IVIg): This is the established cornerstone of therapy for CVID. IVIg replaces the missing antibodies, significantly reducing the frequency and severity of sinopulmonary infections and other complications. This is the standard long-term management strategy.\n\nB. Prophylactic antibiotics with trimethoprim-sulfamethoxazole: Prophylactic antibiotics can be useful as an adjunct for specific infections (e.g., Pneumocystis pneumonia) or if infections remain frequent despite appropriate IVIg dosing, but they do not replace the need for immunoglobulin replacement therapy.\n\nC. Hematopoietic stem cell transplantation (HSCT): HSCT is a potentially curative therapy but is a high-risk procedure. It is typically reserved for patients with severe, life-threatening complications of CVID or those who do not respond to immunoglobulin replacement, such as severe autoimmunity or malignancy. It is not the first-line long-term management strategy for a patient with recurrent infections that would be expected to be managed by IVIg.\n\nD. Rituximab therapy to deplete B cells: Rituximab targets CD20 on B cells. In CVID, there is already a profound defect in B cell function or number leading to antibody deficiency. Depleting B cells further would be detrimental and is contraindicated for the primary management of antibody deficiency.\n\nE. Interleukin-2 supplementation: IL-2 is involved in T cell immunity. While T cell function can be affected in some forms of CVID or related disorders, IL-2 supplementation is not a standard or proven long-term management strategy for the antibody deficiency that characterizes CVID.\n\nTherefore, monthly IVIg replacement is the most appropriate long-term management strategy for this patient.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-007", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "source_question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251201T041413890Z_grok-4-0709_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251201T041413890Z_grok-4-0709_seed124.jsonl", "pred": "A", "model_outputs": "The patient has a known diagnosis of giant cell arteritis (GCA) who is currently on a prednisone taper. They are now experiencing new, alarming symptoms: jaw claudication and vision loss. These are classic signs of worsening or inadequately controlled GCA, particularly ischemic symptoms that threaten permanent vision loss.\n\nThe ESR is elevated at 80 mm/hr, indicating ongoing inflammation, even while on a steroid taper. The CTA showing aortic arch involvement confirms large vessel vasculitis, consistent with GCA. A negative temporal artery biopsy does not rule out GCA, especially when there is strong clinical suspicion and evidence of large vessel involvement.\n\nThe priority in managing GCA with active ischemic symptoms, such as vision loss, is to rapidly suppress inflammation to prevent further irreversible damage. The cornerstone of treatment for GCA with ischemic manifestations is high-dose corticosteroids. Given that the patient is on a *taper*, their current prednisone dose is likely insufficient to control the active disease.\n\nLet's analyze the options:\nA.  Increase prednisone to 60 mg daily: This represents an escalation back to a high-dose corticosteroid regimen, which is the standard initial treatment for GCA presenting with ischemic symptoms like vision loss. Since the patient is on a taper, this increase is a necessary and immediate step to regain control of the inflammation.\nB.  Add methotrexate: Methotrexate is generally used as a steroid-sparing agent to help reduce the cumulative corticosteroid dose, particularly in patients with frequent relapses or steroid-related toxicities. It is not the primary escalation for acute, severe disease with vision loss.\nC.  Initiate tocilizumab: Tocilizumab is a highly effective biologic agent for GCA and is recommended as an adjunctive therapy to corticosteroids, especially in patients with severe disease or high risk of relapse. It can be used to improve remission rates and potentially allow for faster steroid tapering. While adding tocilizumab is a very appropriate strategy *alongside* high-dose steroids in this scenario, the *most immediate escalation* for active ischemic symptoms when GCA patients are on a taper primarily involves returning to high-dose steroids.\nD.  Start cyclophosphamide: Cyclophosphamide is a cytotoxic agent typically reserved for more severe or refractory forms of vasculitis, or specific conditions like GPA or MPA. It is not a first-line or standard second-line therapy for GCA.\nE.  Perform temporal artery ultrasound: While ultrasound can be a diagnostic tool for GCA, the patient already has a presumed diagnosis (being on a taper) and significant clinical evidence of active vasculitis (jaw claudication, vision loss, aortic arch involvement). Further diagnostic imaging is not the most appropriate immediate escalation in therapy to address the sight-threatening emergency.\n\nThe patient is experiencing a severe flare while on a prednisone taper. The most critical and immediate step is to increase the immunosuppression to a level that can quickly control the inflammation and preserve vision. Returning to high-dose prednisone (e.g., 60 mg daily) is the most appropriate initial escalation in this context. Adding tocilizumab would be a strong consideration for adjunctive therapy once high-dose steroids are initiated, but the immediate priority is to ramp up steroid therapy.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-008", "question": "A 25-year-old man with HIV on antiretroviral therapy presents with headache and seizures. CSF analysis shows lymphocytic pleocytosis, elevated protein, and positive India ink stain. MRI reveals multiple ring-enhancing lesions. CD4 count is 150 cells/μL. What is the most appropriate initial management?", "options": ["Start amphotericin B and flucytosine induction", "Initiate pyrimethamine and sulfadiazine", "Administer acyclovir for herpes encephalitis", "Use intravenous ceftriaxone for bacterial meningitis", "Prescribe albendazole for neurocysticercosis"], "answer": "A", "answer_index": 0, "explanation": "Cryptococcal meningitis in HIV presents with India ink-positive CSF and ring-enhancing lesions, requiring induction with amphotericin B and flucytosine for clearance. Toxoplasmosis lacks India ink positivity, while herpes, bacterial, and parasitic etiologies do not match the CSF findings. Prompt antifungal therapy reduces mortality in this setting.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-011", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "A", "model_outputs": "The patient presents with symptoms suggestive of central nervous system infection (headache, seizures) and has findings on CSF analysis (lymphocytic pleocytosis, elevated protein, positive India ink stain) and MRI (multiple ring-enhancing lesions) in the context of HIV with a CD4 count of 150 cells/μL.\n\nThe positive India ink stain is highly specific for *Cryptococcus neoformans*, indicating cryptococcal meningitis. The presence of multiple ring-enhancing lesions can represent cryptococcomas or inflammatory changes associated with extensive meningeal disease. While CD4 counts below 100 cells/μL are more typically associated with severe cryptococcal meningitis, it can occur at higher CD4 counts, especially in individuals with recent sub-optimal immune reconstitution or if ART was recently initiated. The symptoms and positive stain warrant immediate and aggressive treatment.\n\nLet's evaluate the options:\nA. Start amphotericin B and flucytosine induction: This is the standard recommended initial induction therapy for cryptococcal meningitis in HIV-infected individuals. Amphotericin B (often liposomal) combined with flucytosine is considered the most effective regimen for rapidly clearing the fungal burden and reducing mortality.\nB. Initiate pyrimethamine and sulfadiazine: This is the treatment for toxoplasmic encephalitis, another opportunistic infection that can cause ring-enhancing lesions in HIV patients. However, the positive India ink stain rules out toxoplasmosis as the primary diagnosis needing this treatment.\nC. Administer acyclovir for herpes encephalitis: Acyclovir is used for herpes simplex virus encephalitis. The India ink stain is incompatible with this diagnosis.\nD. Use intravenous ceftriaxone for bacterial meningitis: Bacterial meningitis typically presents with neutrophilic pleocytosis, not lymphocytic, and the India ink stain would be negative.\nE. Prescribe albendazole for neurocysticercosis: Albendazole is used for parasitic infections like neurocysticercosis. The India ink stain is not consistent with this diagnosis.\n\nGiven the definitive positive India ink stain for *Cryptococcus*, the most appropriate initial management is to start antifungal induction therapy. Option A describes this standard induction regimen.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-009", "question": "A 55-year-old man with metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation progresses on osimertinib. Tumor biopsy shows transformation to small cell histology. He has good performance status. What is the most appropriate systemic therapy?", "options": ["Continue osimertinib with added chemotherapy", "Switch to amivantamab", "Initiate etoposide and platinum-based chemotherapy", "Use mobocertinib as targeted therapy", "Administer immune checkpoint inhibitor monotherapy"], "answer": "C", "answer_index": 2, "explanation": "Transformation to small cell lung cancer in EGFR-mutant NSCLC requires treatment as small cell carcinoma with etoposide-platinum chemotherapy, which has shown responses in such cases. Continuing EGFR inhibitors is ineffective post-transformation, while amivantamab and mobocertinib target specific exon 20 insertions but not small cell histology. Immunotherapy has limited efficacy in transformed disease.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "C", "model_outputs": "The patient has metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation that has progressed on osimertinib. Crucially, a tumor biopsy shows transformation to small cell lung cancer (SCLC) histology. This transformation necessitates a change in treatment strategy from that for NSCLC to that for SCLC.\n\nLet's analyze the options:\nA. Continue osimertinib with added chemotherapy: Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) targeting the original NSCLC driver mutation. Transformation to SCLC means the tumor is no longer primarily driven by the EGFR mutation in an NSCLC context. Continuing osimertinib is unlikely to be effective against the SCLC component.\nB. Switch to amivantamab: Amivantamab is a bispecific antibody for EGFR exon 20 insertion NSCLC. Like osimertinib, it targets NSCLC and would not be appropriate for SCLC.\nC. Initiate etoposide and platinum-based chemotherapy: This is the standard first-line treatment for small cell lung cancer (SCLC). Given the histological transformation to SCLC, this is the most appropriate approach. The patient has good performance status, making him a candidate for this regimen.\nD. Use mobocertinib as targeted therapy: Mobocertinib is another EGFR TKI for EGFR exon 20 insertion NSCLC. It is not indicated for SCLC.\nE. Administer immune checkpoint inhibitor monotherapy: While immune checkpoint inhibitors (ICIs) have a role in SCLC treatment (often in combination with chemotherapy for extensive-stage disease), ICI monotherapy is not the standard first-line therapy for SCLC. The cornerstone of first-line treatment for SCLC remains chemotherapy.\n\nTherefore, treating the transformed SCLC histology with standard chemotherapy is the most appropriate next step.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_grok-4-0709_p03", "question_id": "ABMS20260101_grok-4-0709_p03-010", "question": "A 12-year-old boy with hereditary angioedema type I presents with recurrent abdominal pain and facial swelling. Laboratory studies show C1 inhibitor level 20% of normal and low C4. He has breakthrough episodes despite prophylactic danazol. What is the most appropriate escalation in therapy?", "options": ["Switch to tranexamic acid prophylaxis", "Initiate subcutaneous C1 inhibitor replacement", "Add icatibant for on-demand treatment", "Use ecallantide for acute attacks", "Administer fresh frozen plasma infusions"], "answer": "B", "answer_index": 1, "explanation": "Subcutaneous C1 inhibitor replacement is effective for prophylaxis in hereditary angioedema with breakthrough on androgens, providing targeted replacement of the deficient protein. Tranexamic acid is less effective for type I, while icatibant and ecallantide are for acute treatment, not prophylaxis. Fresh frozen plasma carries risks and is not preferred for long-term use.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy/Immunology", "source_quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "source_question_id": "20251216T182308874Z_grok-4-0709_seed131-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/grok-4-0709/20251216T182308874Z_grok-4-0709_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251216T182308874Z_grok-4-0709_seed131.jsonl", "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient is 12 years old with hereditary angioedema type I, characterized by low C1 inhibitor levels and low C4. He is experiencing breakthrough episodes despite being on prophylactic danazol. This indicates that the current prophylactic regimen is insufficient. We need to escalate therapy to improve prophylaxis or manage breakthrough attacks more effectively if prophylaxis cannot be improved.\n\nLet's analyze the options:\nA. Switch to tranexamic acid prophylaxis: Tranexamic acid is an antifibrinolytic and can be used for prophylaxis, but it is generally considered less effective than danazol or C1 inhibitor concentrate, especially when breakthrough attacks are occurring. It's not the primary choice for escalation when current prophylaxis has failed.\n\nB. Initiate subcutaneous C1 inhibitor replacement: For patients with HAE type I who experience frequent or severe attacks, or breakthrough attacks despite oral prophylaxis, long-term subcutaneous C1 inhibitor (C1-INH) replacement therapy is a well-established and highly effective prophylactic treatment. This directly addresses the deficient C1-INH and provides continuous protection. This is a strong candidate for escalating prophylaxis.\n\nC. Add icatibant for on-demand treatment: Icatibant is a bradykinin B2 receptor antagonist used for the *on-demand treatment* of acute HAE attacks. While it is important to have on-demand treatment available, the question asks for the most appropriate *escalation in therapy* when prophylaxis is failing due to breakthrough episodes. Escalating prophylaxis is usually the primary step.\n\nD. Use ecallantide for acute attacks: Ecallantide is a kallikrein inhibitor used for the *on-demand treatment* of acute HAE attacks. Similar to icatibant, it addresses acute symptoms but not the underlying issue of insufficient prophylaxis.\n\nE. Administer fresh frozen plasma infusions: Fresh frozen plasma (FFP) contains C1 inhibitor and can be used acutely or, historically, for prophylaxis. However, it has significant drawbacks, including volume, infection risk, and immunogenicity. Plasma-derived or recombinant C1 inhibitor concentrates are preferred for prophylaxis over FFP due to better standardization, efficacy, and safety profiles.\n\nConsidering the patient is experiencing breakthrough attacks despite danazol prophylaxis, the most appropriate escalation is to improve the prophylactic regimen. Subcutaneous C1 inhibitor replacement is the most effective and targeted option for providing continuous prophylaxis in HAE type I when oral agents are insufficient.\n\nThe answer is (B)"}]